Financial Performance - Revenue for Q4 2024 was a record $12.1 million, up 154% compared to Q4 2023[4] - Full year revenue for 2024 was $32.6 million, representing a 69% increase compared to 2023[10] - The company expects 2025 revenue to be between $50 million and $53 million, an increase of 54% to 63% compared to 2024[13] - Product revenue for Q4 2024 reached $12,068,456, a significant increase of 153% compared to $4,756,383 in Q4 2023[24] Cash Flow and Profitability - The company generated its first-ever positive cash flow from operations of $3.4 million in Q4 2024[12] - Adjusted EBITDA for Q4 2024 was $0.2 million, marking the first positive Adjusted EBITDA in the company's history[9] - Net loss for the year ended December 31, 2024, was $6,183,729, an improvement from a net loss of $8,147,565 in 2023[28] - Adjusted EBITDA for the year ended December 31, 2024, was $(5,126,350), an improvement from $(6,952,426) in 2023[30] - The company reported a net cash used in operating activities of $(3,289,904) for the year ended December 31, 2024, compared to $(6,172,764) in 2023, indicating improved cash flow management[28] Operational Metrics - A record 233 MyoPro units were authorized and ordered in Q4 2024, an increase of 27% year-over-year[11] - The patient pipeline reached 1,389 candidates as of December 31, 2024, up 33% from the previous year[11] - The backlog of orders as of December 31, 2024, was 272 units, up 18% year-over-year[11] Cost and Expenses - Operating expenses for Q4 2024 were $8.9 million, a 60% increase compared to Q4 2023[7] - Operating expenses for the year increased to $29,392,041 in 2024, compared to $21,413,932 in 2023, reflecting a 37% increase[24] Profitability Metrics - Gross margin improved to 71.4% in Q4 2024, up from 65.3% in Q4 2023[6] - Gross profit for the year ended December 31, 2024, was $23,185,343, up from $13,182,383 in 2023, reflecting a 76% increase[24] Assets and Liabilities - Total current assets increased to $32,789,996 in 2024, compared to $13,650,983 in 2023, representing a growth of 140%[25] - Cash and cash equivalents rose to $24,372,373 in 2024, compared to $6,871,306 in 2023, marking a 254% increase[25] - Total liabilities increased to $17,530,022 in 2024, compared to $5,592,218 in 2023, representing a growth of 213%[25] Shareholder Information - The weighted average number of common shares outstanding increased to 37,758,837 in 2024 from 29,499,340 in 2023[24]

Financial Data and Key Metrics Changes - Revenue for Q3 2024 reached a record $9.2 million, up 83% year-over-year, driven by increased MyoPro volume and a higher average selling price (ASP) of approximately $57,200 [7][13] - The operating loss for Q3 2024 was $1 million, a reduction from a $2 million loss in the same period last year [17] - Net loss for Q3 2024 was $1 million or $0.03 per share, compared to a net loss of $2 million or $0.06 per share for Q3 2023 [17] - Gross margin for Q3 2024 was 75.4%, up from 68.7% in the prior year quarter, primarily due to higher ASP and fixed cost absorption [17] Business Line Data and Key Metrics Changes - The company added 645 medically qualified candidates to the patient pipeline, a 69% increase year-over-year [6] - Insurance authorizations and orders for MyoPro reached a record 225 units in Q3, up 44% year-over-year [6] - Revenue units delivered totaled 161 MyoPros, a 35% increase from the previous year [7] Market Data and Key Metrics Changes - 55% of product revenue in Q3 came from Medicare Part B patients, up from 47% in the previous quarter [14] - Revenue from Medicare Advantage plans represented 24% of Q3 revenue, down 26% year-over-year due to a challenging reimbursement environment [14] Company Strategy and Development Direction - The company aims to expand its distribution channel by engaging orthotics and prosthetics clinics across the U.S. and establishing contracts with payers for in-network status [5][10] - The focus is on building the O&P distribution channel while continuing to grow the direct provider business [42] - The company plans to move to a larger production facility to accommodate expected growth and shipments [11] Management's Comments on Operating Environment and Future Outlook - Management expressed frustration with some Medicare Advantage plans making it difficult for patients to receive care, leading to increased denials and appeals [9] - Positive developments were noted as some previously non-reimbursing Medicare Advantage plans began to cover MyoPro [10] - The company expects to achieve record revenue in Q4 2024, with guidance of $9.5 million to $10.5 million, representing 100% to 121% year-over-year growth [22] Other Important Information - The company has entered into contracts with Blue Cross Blue Shield of Massachusetts and Paradigm, covering 3 million lives [10] - International operations, particularly in Germany, generated $1.1 million in revenue for Q3 2024 [12] - The company is preparing for a new facility that will increase production capacity and is expected to be operational by the end of the year [21] Q&A Session Summary Question: What percentage of Part B patients is supplemental insurance or Medicaid covering? - Approximately 20% to 25% of patients have supplemental insurance coverage, which impacts revenue recognition [29] Question: How quickly can O&P providers start generating revenue? - Initial orders from O&P providers are expected to materialize within six months after training [32] Question: What is the current production capacity and plans for the new facility? - Current production capacity is exceeding 80 units per month, with plans to double capacity in the new facility [34][35] Question: What is the value of the backlog and when will it be recognized? - The backlog of 316 units has a net value of over $10 million, with approximately 35% to 40% expected to turn into revenue one quarter out [45][47] Question: What are the international expansion plans? - The focus is on ramping up operations in Germany, with potential future expansions into France and Italy [50] Question: Any updates on R&D developments? - Enhancements to the MyoPro are in progress, with announcements expected in Q1 2025 [52]

Company Performance - Myomo, Inc. reported a quarterly loss of $0.03 per share, better than the Zacks Consensus Estimate of a loss of $0.04, and an improvement from a loss of $0.06 per share a year ago, representing an earnings surprise of 25% [1] - The company posted revenues of $9.21 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 15.82%, and up from $5.08 million in the same quarter last year [2] - Over the last four quarters, Myomo has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Outlook - Myomo shares have declined approximately 21% since the beginning of the year, contrasting with the S&P 500's gain of 21.2% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.01 on revenues of $9.45 million, and for the current fiscal year, it is -$0.18 on revenues of $28.62 million [7] - The estimate revisions trend for Myomo is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Products industry, to which Myomo belongs, is currently ranked in the top 36% of over 250 Zacks industries, suggesting that companies in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8]

Revenue Performance - Revenue for the third quarter of 2024 was $9.2 million, up 81% compared to the third quarter of 2023[2] - Product revenue increased 83% year-over-year, driven by a record 161 MyoPro units sold, up 35%[4] - Product revenue for the three months ended September 30, 2024, was $9,207,586, a 83.3% increase from $5,029,523 in the same period of 2023[19] - The company expects fourth quarter revenue to be in the range of $9.5 million to $10.5 million, raising full-year revenue guidance to $30 million to $31 million[11] Patient and Order Metrics - The patient pipeline reached 1,263 patients, an increase of 21% year-over-year, with 645 new candidates added in the third quarter, up 69%[9] - Backlog of orders and insurance authorizations was a record 316 units, up 71% compared to the same period last year[2] Financial Performance - Gross margin for the third quarter was 75.4%, an increase of 670 basis points from 68.7% in the same quarter of 2023[5] - Adjusted EBITDA for the third quarter was $(0.6) million, an improvement from $(1.7) million in the same quarter of 2023[8] - Net loss for the nine months ended September 30, 2024, was $5,923,648, compared to a net loss of $5,687,461 for the same period in 2023[22] - Adjusted EBITDA for the nine months ended September 30, 2024, was $(5,294,458), compared to $(4,886,541) for the same period in 2023[23] Operating Expenses - Operating expenses for the third quarter were $7.9 million, a 43% increase compared to the third quarter of 2023[6] - Operating expenses for the three months ended September 30, 2024, totaled $7,903,108, up from $5,513,217 in the same period of 2023, indicating a 43.4% increase[19] - Research and development expenses for the three months ended September 30, 2024, were $1,248,870, compared to $717,256 in the same period of 2023, reflecting a 74.1% increase[19] Cash and Assets - Cash, cash equivalents, and restricted cash as of September 30, 2024, were $7.0 million, with cash used in operating activities at $1.5 million for the third quarter[10] - Cash and cash equivalents at the end of the period were $6,997,675, slightly up from $6,911,747 at the end of the same period in 2023[22] - Total current assets increased to $14,704,144 as of September 30, 2024, from $13,650,983 at December 31, 2023, reflecting an 7.7% growth[21] - Total liabilities rose to $7,020,537 as of September 30, 2024, compared to $5,592,218 at December 31, 2023, marking a 25.5% increase[21] Shareholder Information - The company reported a weighted average number of common shares outstanding of 37,950,515 for the three months ended September 30, 2024, compared to 35,266,361 for the same period in 2023[19] Strategic Initiatives - The company launched its orthotics and prosthetics channel program in September 2024, aiming for growth in this area in 2025 and beyond[2]

Financial Data and Key Metrics Changes - Revenue for Q2 2024 was $7.5 million, up 77% year-over-year, with total revenue increasing by 26% compared to the same quarter last year [12][13] - Product revenue growth was driven by a 63% increase in revenue units and a higher average selling price (ASP) of approximately $47,500, up 9% year-over-year [13][14] - Gross margin for Q2 2024 was 70.8%, slightly down from 71.8% in the prior year, primarily due to the impact of high-margin license revenue in the previous year [17][18] - Operating loss for Q2 2024 was $1.1 million, unchanged from Q2 2023, while net loss was $1.1 million or $0.03 per share, compared to a net loss of $1 million or $0.04 per share in the prior year [19][20] Business Line Data and Key Metrics Changes - The company recognized revenue on 74 MyoPros delivered to Medicare Part B beneficiaries, contributing to a record number of patient pipeline additions and authorizations [6][7] - The patient pipeline reached 1,179 patients, with 550 additions in Q2, marking a 35% year-over-year increase [16] - Revenue from Medicare Advantage plans represented 26% of total revenue, down 26% year-over-year due to a more challenging reimbursement environment [14] Market Data and Key Metrics Changes - International operations, primarily in Germany, generated over $1 million in revenue during the quarter [10] - The company has seen a positive trend with some Medicare Advantage plans starting to remit payments at the Medicare rate, contributing to the higher ASP [9] Company Strategy and Development Direction - The company plans to expand its manufacturing capacity and is finalizing plans to move to a larger production facility in the Boston area [10][24] - There is a focus on building relationships with O&P clinics and training clinicians to become MyoPro centers of excellence, with a goal of training 80 to 100 clinicians by the end of the year [30][51] - Increased investment in R&D is planned to innovate product development and maintain a first-mover advantage in the market [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue growth in the third quarter, expecting revenue in the range of $8.0 million to $8.5 million, representing a year-over-year growth of 58% to 67% [22] - The company anticipates that the second half of the year will be stronger than the first half, historically seeing better performance in the latter half due to patient out-of-pocket expenses resetting at the beginning of the year [46][47] Other Important Information - The company has entered into a $4 million accounts receivable line of credit with Silicon Valley Bank to support operations [21] - The company expects to file a new shelf registration statement shortly to maintain a valid registration for future offerings [21] Q&A Session Summary Question: Confidence around increasing manufacturing capacity - Management indicated plans to expand capacity beyond 80 units per month by Q4 and potentially add a second shift next year [28] Question: Goals for the O&P channel team - The focus is on building relationships and training clinicians this year, with material revenue expected to build in 2025 [30] Question: Gross margins outlook - Management views 70% as a good baseline for gross margins, with potential for expansion as more Medicare Advantage plans reimburse at the Medicare allowable rate [34] Question: Impact of political advertising on pipeline - Management acknowledged that political advertising could create competition for patient attention in Q3 and Q4, but they are increasing advertising spend to mitigate this [39] Question: Increasing marketing without impacting bottom line - Management is balancing increased marketing spend with the goal of achieving operating cash flow breakeven in Q4 while ensuring revenue growth in 2025 [44]

INVESTOR PRESENTATION AUGUST 2024 Paul R. Gudonis, Chairman and CEO David Henry, CFO Conquering Upper Limb Paralysis with Wearable Medical Robotics NYSE American: MYO 1 NYSE American: MYO Overview Market Opportunity Insurance Reimbursement Product Line & Evidence Commercial Scale Up Financials Legal Disclaimer This presentation contains forward-looking statements regarding the trading of the Company's common stock on the NYSE American, the Company's plans for the use of proceeds and advancing its product li ...

Revenue Growth - Product revenue for the three months ended June 30, 2024, increased by approximately $3,277,100, or 77%, compared to the same period in 2023, reaching $7,520,767[84] - Total revenue for the six months ended June 30, 2024, increased by approximately $1,869,900, or 20%, compared to the same period in 2023, totaling $11,275,156[84] - Revenues from Medicare Part B beneficiaries represented 47% and 35% of product revenues for the three and six months ended June 30, 2024, respectively[80] Gross Margin - Gross margin for product revenue was 70.8% for the three months ended June 30, 2024, compared to 60.5% for the same period in 2023[85] Operating Expenses - Operating expenses for the three months ended June 30, 2024, totaled $6,440,576, an increase of 20% compared to $5,384,062 for the same period in 2023[87] - SC&M expenses rose by approximately $505,200 (22%) and $836,500 (19%) during the three and six months ended June 30, 2024, respectively, driven by increased headcount and higher travel costs[90] - G&A expenses increased by approximately $108,300 (4%) and $507,000 (10%) for the three and six months ended June 30, 2024, respectively, mainly due to higher payroll costs and increased legal fees[92] Research and Development - Research and development expenses increased by 79% to $1,007,224 for the three months ended June 30, 2024, compared to $564,235 for the same period in 2023[87] - R&D expenses increased by approximately $443,000 (79%) and $922,200 (89%) for the three and six months ended June 30, 2024, compared to the same periods in 2023, primarily due to higher payroll costs[89] Net Loss and Cash Flow - The company reported a net loss of $1,121,607 for the three months ended June 30, 2024, compared to a net loss of $1,014,150 for the same period in 2023[97] - The company used approximately $5.2 million in cash for operating activities during the six months ended June 30, 2024, compared to $2.1 million for the same period in 2023[101] - The company anticipates continued net losses and negative cash flows as it expands sales and marketing efforts and invests in product development[81] Financial Position - As of June 30, 2024, the company had cash and cash equivalents of approximately $5.8 million and total working capital of approximately $8.7 million[98] - The company generated net proceeds of approximately $5.4 million from a registered direct equity offering completed in January 2024[99] - The company entered into a Loan and Security Agreement with Silicon Valley Bank, allowing it to borrow up to $4.0 million against eligible accounts receivable[99] Future Plans - The company plans to hire 50 to 60 people through the second quarter of 2024 to increase clinical, reimbursement, and manufacturing capacity[78] - The company plans to increase clinical, reimbursement, and manufacturing capacity, aiming for cash flow breakeven by the fourth quarter of 2024[101] Regulatory and Market Information - The Centers for Medicare and Medicaid Services (CMS) published final average payment determinations of approximately $33,500 for MyoPro Motion W and $65,900 for MyoPro Motion G, effective April 1, 2024[79] - The joint venture in China has a minimum purchase commitment of $10.75 million for MyoPro Control System units over the next ten years[77] - Recent accounting standards are detailed in Note 3 of the unaudited condensed consolidated financial statements[106] - Item 3 regarding quantitative and qualitative disclosures about market risk is not applicable as the company is classified as a smaller reporting company[107]

Revenue Performance - Record revenue of $7.5 million for Q2 2024, up 26% year-over-year, with product revenue increasing 77%[1] - Year-to-date revenue for 2024 was $11.3 million, up 20% compared to the same period in 2023[3] - The company expects Q3 2024 revenue to be in the range of $8.0 million to $8.5 million, with a full-year revenue expectation of $28 million to $30 million[8] - Product revenue for the three months ended June 30, 2024, was $7,520,767, a 77% increase from $4,243,624 in the same period of 2023[15] Patient Pipeline and Authorizations - 213 MyoPro authorizations and orders received, representing a 70% increase compared to Q2 2023[1] - Patient pipeline reached 1,179 candidates, up 22% year-over-year, with 550 new candidates added in Q2 2024, a 35% increase[1] - Cost per pipeline add decreased to $1,545, down 26% compared to Q2 2023[5] Financial Metrics - Gross margin for Q2 2024 was 70.8%, down 100 basis points from 71.8% in Q2 2023, while gross margin on product revenues increased by 1,030 basis points[1][4] - Gross profit for the six months ended June 30, 2024, was $7,624,555, compared to $6,588,658 for the same period in 2023, reflecting a 15.8% increase[15] - Operating expenses for Q2 2024 were $6.4 million, a 20% increase compared to Q2 2023, driven by higher payroll expenses[5] - Operating expenses for the three months ended June 30, 2024, totaled $6,440,576, up from $5,384,063 in the same period of 2023, representing a 19.6% increase[15] Losses and Cash Flow - Year-to-date operating loss was $5.0 million, compared to a loss of $3.8 million for the same period in 2023[6] - Net loss for the six months ended June 30, 2024, was $4,957,239, compared to a net loss of $3,658,445 for the same period in 2023, indicating a 35.4% increase in losses[17] - Net cash used in operating activities for the six months ended June 30, 2024, was $5,161,488, compared to $2,102,213 for the same period in 2023, indicating a significant increase in cash outflow[17] - Adjusted EBITDA for the six months ended June 30, 2024, was $(4,709,773), compared to $(3,227,923) for the same period in 2023, showing a worsening of 46%[18] Cash Position and Assets - Cash position as of June 30, 2024, was $9.0 million, with cash used in operating activities of $1.9 million for Q2 2024[9] - Cash and cash equivalents at the end of June 30, 2024, were $5,846,100, down from $6,871,306 at the end of December 31, 2023[16] - Total assets increased to $16,190,381 as of June 30, 2024, compared to $14,581,568 as of December 31, 2023, marking an 11% growth[16] - Total stockholders' equity rose to $9,677,711 as of June 30, 2024, from $8,989,350 at the end of December 31, 2023, reflecting a 7.7% increase[16] Shareholder Information - The weighted average number of common shares outstanding increased to 37,368,488 for the three months ended June 30, 2024, from 27,992,928 in the same period of 2023[15]

Exhibit 99.1 Myomo Reports First Quarter 2024 Financial Results Record 275 patients in backlog, includes 180 authorizations and orders in Q1, up 48% over the prior year Record 493 MyoPro candidates added to the pipeline in Q1 Revenue of $3.8 million, up 9% over the prior year Conference call begins at 4:30 p.m. Eastern time today BOSTON (May 8, 2024) – Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-38109 MYOMO, INC. (Exact name of Registrant as Specified in its Charter) Delaware 47-0944526 (State or Other Jurisdiction of ( ...